Sign in

    Matt Marcus

    Research Analyst at Jefferies Financial Group Inc.

    Matt Marcus is an Analyst at Jefferies Financial Group Inc., specializing in equities and capital markets with a particular focus on technology and delta one strategies. Within his role, Marcus contributes expert analysis and research relevant to investment banking, though specific companies he covers are not detailed in available sources nor are concrete performance metrics recorded on public ranking platforms. His career has developed within Jefferies, contributing to equities research and investment strategy, but precedents from other firms or his start date are not specified in public records. Details on his professional credentials, such as FINRA registrations or securities licenses, are not publicly accessible.

    Matt Marcus's questions to Xenon Pharmaceuticals (XENE) leadership

    Matt Marcus's questions to Xenon Pharmaceuticals (XENE) leadership • Q4 2024

    Question

    Matt Marcus of Jefferies, on for Andrew Tsai, inquired about the minimum efficacy threshold for Azetukalner to achieve best-in-class status in focal epilepsy and asked about the expected granularity of the upcoming Phase II MDD data from the Mount Sinai study.

    Answer

    President and CEO Ian Mortimer explained that for the Phase III epilepsy study, the primary goal is achieving statistical significance to support an NDA filing, emphasizing the drug's overall strong profile. Regarding the investigator-sponsored MDD study, he expects to publicly share data on the primary functional MRI endpoint and key secondary clinical scales like MADRS and SHAPS in the first half of 2025.

    Ask Fintool Equity Research AI